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ABSTRACT 
Objective: The rationale for the study was to develop a once-daily dose of immediate as well as a gastro-retentive form of carvedilol phosphate by 
compression coating floating technique. 
Methods: In the presented study the core tablet was containing half the quantity of the drug formulated as floating drug delivery using different 
controlled release polymers blend in various proportions like ethyl cellulose, carbopol, hydroxypropyl methylcellulose (HPMC) K4, K15, and K100 
by direct compression method. Outer coat layer was formulated with rest of the drug with the blend of different super disintegrants in various 
proportions like crospovidone, croscarmellose sodium (CCS), sodium starch glycolate (SSG) for the immediate release of the drug. Both the 
immediate and controlled formulation was separately formulated from sf1 to sf9 and f1 to f9 respectively. Based on the evaluation parameters 
finally, formulation F1 to F9 were formulated by applying compression coating floating method. These formulations were characterized for their 
tablet density, disintegration time, floating lag time, in vitro drug release, drug-excipients interaction and accelerated stability studies etc. 
Results: The result revealed formulation sf9 containing SSG of 15% was able to 97.2% of drug release within 15 min towards the achievement of 
immediate release. Similarly, the formulation f9 containing 0.5:0.5:4.5 ratios of ethyl cellulose, carbopol and HPMC K15 was able to 95.3% of drug 
release within 16h. From compressed coat tablets batches of F1 to F9, based on the dissolution data F9 was considered as an optimized formulation 
which was able to release 48.6% of drug release within 15 min and cumulatively controlled the release up to 96.4% for 16 h, followed zero-order 
kinetics and Higuchi pattern.  
Conclusion: The results obtained in this research work clearly indicated that the compression coating floating tablet of carvedilol phosphate was 
the best dosage form for the treatment of hypertension. Results of the evaluation of prepared batches indicate that the batch F9 is a promising 
formulation for both a quick onset of action as well as gastro-retentive dosage form to maintain the constant drug action which would improve the 
maximum therapeutic efficacy and patient compliance. 
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Carvedilol phosphate is the drug of choice in the treatment of 
hypertension and congestive heart failure. Carvedilol phosphate is a 
class II drug which has low solubility and high permeability, 
practically insoluble in water, have a slow onset of action and poor 
bioavailability [1]. Therefore it could not be ideal to be given in an 
emergency clinical situation like hypertension and heart failure. For 
better therapeutic effect, immediate and prolonged duration of 
action both is needed. The purpose of this research was to first 
dissolute and release the drug immediately for a quick onset of 
action and then to maintain the dosage form of control over a period 
of time. So this research is designed with a dual approach such as 
compression coating technique, where the core would be a gastro-
retentive floating tablet and the coating material is to provide a 
quick onset of action. Hurdles in such formulation were identified as 
the low solubility, high permeability of carvedilol phosphate, which 
caused the poor oral bioavailability. Due to its poor bioavailability, it 
exerts strong effects on the performance of drug and leads to the 
necessity to give a higher dose for attaining required 
pharmacological action, which may cause serious side effects like 
gastric irritation. Therapy should be individualized according to 
patient response to attain maximum therapeutic response with 
minimal dose. Drug which is practically insoluble in gastric fluid and 
having high permeability through the stomach but due to its 
solubility limitations, in the gastric fluid it could not enter into the 
systemic circulation [2, 3]. Whereas in the small intestine the drug is 
soluble but cannot permeate through the membrane due to its 
permeation limitation [4]. To improve bioavailability and to reduce 
dosing frequency, a suitable formulation was required with a 
controlled rate towards the treatment of hypertension and 
congestive heart failure.  
In the present study, the compression coating, floating tablets of 
carvedilol phosphate were designed and developed from that coat 
layer causes immediate release and coat with controlled layer 
polymers using a hydrophilic polymer, hydroxypropyl methyl-
cellulose (HPMC K100, K15 and K4) and ethyl cellulose, in 
combination with carbopol to release for a prolong duration. The 
compression coating floating tablet may overcome all above 
limitation which may exhibit benefits to improve the bioavailability, 
therapeutic efficacy with reduction of side effects. This would be 
benefit towards the treatment of severe hypertension with 
prolonged drug action [5-7].  
Carvedilol phosphate is a non-selective beta blocker indicated in the 
treatment of mild to moderate congestive heart failure (CHF). It 
blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-1 
adrenergic receptors [8]. It is a weakly basic drug, with low 
solubility in alkaline pH. It is available as odorless, crystalline 
powder. Carvedilol phosphate is more than 98% bound to plasma 
proteins, primarily with albumin. The plasma-protein binding is 
independent of concentration over the therapeutic range. Carvedilol 
phosphate is a basic, lipophilic compound with a steady-state 
volume of distribution of approximately 115 liter, indicating 
substantial distribution into extravascular tissues.  
Carvedilol phosphate is metabolized primarily by aromatic ring 
oxidation and glucuronidation. The oxidative metabolites are further 
metabolized by conjugation via glucuronidation and sulfation. 
Demethylation and hydroxylation at the phenol ring produce three 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 10, Issue 6, 2018 
Panda et al. 
Int J Pharm Pharm Sci, Vol 10, Issue 6, 82-89 
83 
active metabolites with b-receptor blocking activity. The 4-
hydroxyphenyl metabolite is approximately 13 times more potent 
than carvedilol phosphate for b-blockade. Less than 2% of the dose 
was excreted unchanged in the urine. The metabolites of carvedilol 
phosphate is excreted primarily via the bile into the fecal [9-11]. 
MATERIALS AND METHODS 
Materials 
Carvedilol phosphate was obtained as a gift sample from 
Yarrowchem Products, Mumbai. Lactose was purchased from 
Suvidhinath Laboratories, Baroda. HPMC different grades were 
purchased from Loba Chemie Ltd, Mumbai. Crospovidone, 
croscarmellose sodium (CCS), sodium starch glycolate (SSG) were 
purchased from Hetero Pharma Ltd., Hyderabad. Sodium 
bicarbonate, microcrystalline cellulose (MCC) were purchased from 
Qualigens Fine Chemicals, Mumbai. Ethyl cellulose and carbopol 
were purchased from Finar Chemicals Ltd, Ahmadabad, India. All 
other ingredients used were of analytical grade. 
Methodology 
Preparation of carvedilol phosphate core controlled-release tablets 
The core layer of 350 mg obtained from different polymeric 
mixtures of different ratios was taken. The inner core tablets were 
prepared by using direct compression method. A powder mixture of 
carvedilol phosphate, HPMC K100, K15, K4, ethyl cellulose, carbopol, 
citric acid, sodium bicarbonate and lactose ingredients were dry 
blended for 20 min followed by the addition of magnesium stearate 
and talc. The mixture was then further blended for 10 min. 350 mg 
of resultant powder blend was manually compressed using 8 mm 
punch diameter as mentioned in table 1. 
 
Table 1: Composition of carvedilol phosphate floating tablets (f1-f9) 
Batch code Drug: polymer ratio Polymer ratio 
f1 1:3 0.5:0.5:2 (Ethyl cellulose: carbopol: HPMC K4) 
f2 1:5 0.5:0.5:4 (Ethyl cellulose: carbopol: HPMC K4) 
f3 1:7 0.5:0.5:6 (Ethyl cellulose: carbopol: HPMC K4) 
f4 1:1.25 0.5:0.5:0.25 (Ethyl cellulose: carbopol: HPMC K100) 
f5 1:1.5 0.5:0.5:0.5 (Ethyl cellulose: carbopol: HPMC K100) 
f6 1:1.75 0.5:0.5:0.75 (Ethyl cellulose: carbopol: HPMC K100) 
f7 1:3 0.5:0.5:2 (Ethyl cellulose: carbopol: HPMC K 15) 
f8 1:5 0.5:0.5:4 (Ethyl cellulose: carbopol: HPMC K 15) 
f9 1:5.5 0.5:0.5:4.5 (Ethyl cellulose: carbopol: HPMC K 15) 
 
Preparation of carvedilol phosphate immediate release tablets 
as a coating material 
The coat layer of 100 mg obtained from different polymeric mixtures of 
different ratios were taken. A powder mixture of carvedilol phosphate, 
MCC, lactose, SSG, crospovidone and CCS were dry blended for 20 
minutes followed by addition of magnesium stearate. The mixture was 
then further blended for 10 min. 100 mg of resultant powder blend was 
manually compressed with 6 mm punch diameter to obtain the coat 
tablet for preliminary studies as mentioned in table 2. 
 
Table 2: Composition of immediate release tablets for coat materials (sf1-sf9) 
 Batch code Drug: polymer ratio Polymer ratio to total blend 
sf1 1:0.25 Crospovidone(5%) 
sf2 1:0.5 Crospovidone(10%) 
sf3 1:0.75 Crospovidone(15%) 
sf4 1:0.25 Croscarmellose sodium(5%) 
sf5 1:0.5 Croscarmellose sodium(10%) 
sf6 1:0.75 Croscarmellose sodium(15%) 
sf7 1:0.25 Sodium starch glycolate(5%) 
sf8 1:0.5 Sodium starch glycolate (10%) 
sf9 1:0.75 Sodium starch glycolate (15%) 
 
Preparation of carvedilol phosphate compression coating 
floating tablets 
Coating material containing 50% equivalent of the drug was placed 
in the die cavity of 9 mm punch diameter. The core tablet was then 
placed in the centre of the die cavity, which was filled with the 
remainder of the coat formulation and compressed. Based on 
preliminary trials on the carvedilol phosphate compression coating 
floating tablets, formulation of F1 to F9 were designed and evaluated 
for the release profile of both immediate release and for controlled 
release profile of carvedilol phosphate.  
Evaluation tests for compression coating floating tablets 
Compression coating floating tablets were separated into immediate 
release (IR) and sustained release (SR) layer. Assays were 
performed for both IR and SR layers separately. To each of the layer, 
the following estimation procedure was carried out. 
Pre-formulation studies 
The following pre-formulation studies were performed with 
carvedilol phosphate dry blend with formulation components.  
Angle of repose 
The frictional forces in a loose powder can be measured by the angle 
of repose ‘θ’. It is defined as the maximum angle possible between 
the surface of a pile of powder and the horizontal plane. It is 
determined by the fixed funnel and free-standing cone method. An 
accurately weighed 5 g powders of carvedilol phosphate were 
carefully poured into the funnel with its tips about 2 cm height (h) 
until the apex of the conical heap formed to be just reached the tip of 
the funnel [12]. The mean diameter (r) and height were calculated 
and the angle of repose (θ) was calculated by using formula θ = tan-
Bulk density and tapped density 
1 
(h/r). 
A quantity of 5 gm of carvedilol phosphate, previously lightly shaken 
to break any agglomerates formed, was introduced into a 10 ml 
measuring cylinder of the tapped density apparatus maker of 
Campbell electronics, Mumbai. The initial volume was observed and 
the cylinder was allowed to hit a height of 2.5 cm at 2 s intervals 
until there were no further changes in volume. Both bulk density 
(Db) and tapped bulk density (Dt) were determined.  
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Carr’s index (I): It indicates the ease with which a material can be 
induced to flow. It is expressed in percentage and is given by  
I = (Dt − Db/Dt )100 
Where ‘Dt’ is the tapped density and ‘Db’ is the bulk density of the 
powder. 
Hausner’s ratio 
This indicates the flow properties of the powder and measured by 
the ratio of tapped density to the bulk density. 
Physical evaluation tests 
The tablets were tested for post-compression quality control tests 
like hardness, friability, weight variation, disintegration test, tablet 
thickness and in vitro buoyancy studies.  
Hardness 
Tablets require a certain amount of strength or hardness and 
resistance to friability, to withstand the mechanical shock of 
handling in manufacture, packaging and also in shipping. The 
hardness was tested for 6 tablets from each formulation batch using 
Monsanto hardness tester [13].  
Friability testing 
Friability is the tendency for a tablet to chip, break or crumble 
following compression. Tablets need to be hard enough so that they do 
not break up in the bottle but friable enough to disintegrate in the 
gastrointestinal tract. As specified in the United State Pharmacopoeia 
(USP) weight variation test was run by taking 10 tablets. The weight 
(W1) of those tablets was determined before re dusted prior to 
weighing. The tablets were then placed in a test drum of friability 
tester ‘FR1000’ of Copley Scientific, Mumbai, India and allowed to 
rotate for 100 times. The tablets were reweighed (W2) having first 
removed accumulated dust to them. The result was calculated in terms 





The maximum weight loss not less than 1% be normally acceptable [14].  
Swelling studies 
Sustained released dosage forms were weighed individually (w1) 
and placed separately in petri dishes containing 4 ml of medium. At 
regular interval viz. 0.5, 1, 2, 3, 4, 5h the dosage forms were removed 
from the petri dishes and excess surface water was removed by 
using filter paper. The dosage forms were reweighed (w2) and 





Where w1 was the initial and w2 was the final weight of the tablet. 
Tablet density 
Tablet density (ρ) is an important parameter for floating tablets. The 
tablet floats when its density is less than that of gastric fluid (1.004 
g/cc). The tablet density was determined by using following formula 
[16].  





Where v = volume of the tablet (cc); r = radius of the tablet (cm); h = 
crown thickness of the tablet (mm); m = mass of the tablet.  
Disintegration test 
To test for disintegration time, one tablet was placed in each tube, 
and the basket rack was positioned in a 1-liter beaker of the medium 
at 37±2 °C. The standard motor driven device was used to move the 
basket assembly containing the tablets up and down through a 
distance of 5 to 6 cm at a frequency of 28 to 32 cycles per minute. 
Perforated plastic discs were placed on top of the tablets [17]. 
In vitro buoyancy and total floating time studies  
The in vitro buoyancy was determined by floating lag time. 
Formulated tablets of each batch were placed in a 100 ml beaker 
containing 0.1N HCl and the time required for the each table to rise 
to the surface was determined as floating lag time. The total floating 
time of granules in each batch was also recorded [18]. 
In vitro drug release studies  
In vitro dissolution studies were performed in a USP XXIII dissolution 
test apparatus, type II (paddle method) (Disso 2000, Lab India, India) 
at 37±0.5 °C and with a paddles rotation speed of 50 rpm. The 
compression coating floating tablets were placed into 900 ml of 0.1 N 
HCl solution (pH 1.2) as the dissolution medium. The tablets were 
placed in 316 stainless steel sinkers which kept them in sink condition 
during the dissolution study. Dissolution studies were carried out in 
triplicate. 10 ml aliquots of samples were collected at 1h interval up to 
16 h. They were filtered and estimated for carvedilol phosphate 
release using UV-visible spectrophotometer at 241 nm. At each time of 
withdrawal, 10 ml of fresh medium was replaced into the dissolution 
flask. The concentrations were calculated using the standard 
calibration curve prepared using 0.1N HCl as a solvent. The cumulative 
percentage of carvedilol phosphate released from compression coating 
floating tablets was calculated [19].  
Release kinetic study 
To study the release kinetics, the data obtained from in vitro drug 
release studies were plotted in various kinetic models as follows:  
1. Zero-order: Cumulative % of drug released versus time;  
2. First order: Log cumulative % of drug remaining versus time;  
3. Higuchi: Cumulative % of drug released versus square root of 
time; and 
4. Korsmeyer–Peppas: Log cumulative % of drug released versus log 
time. 
The linearity of the plots was obtained from the values of regression 
coefficient (R2). The model with the highest linearity (R2
Accelerated stability studies 
 value 
approaching unity) was chosen as the best fit kinetic model [20]. 
Short-term accelerated stability testing was carried out according to 
ICH guidelines considering 40±2 °C/75±5% relative humidity (RH) 
in a stability chamber for a period of 6 mo. The compression coating 
floating tablets of optimized formulation was subjected to stability 
chamber at a minimum of three-time points, including the initial, 
intermediate and final time points (e. g., 0, 3, and 6 mo). At the end of 
3rd and 6 mo of the tablets exposed to stability chamber were again 
analyzed for their physical appearance, assay (%) and in vitro drug 
release profile at 1st,2nd, 12th and 16th
RESULTS AND DISCUSSION 
 h [21]. 
Micromeritic properties of the pre-compressed powder blend 
Micromeritic properties of pre-compressed powder blend were 
evaluated and cited in table 3. The angle of repose found to be within 
the limit of 20.34±0.04 to 29.88±0.24. Bulk density was found 
between 0.105 to 0.129 g/cc and tapped density was between 0.112 
to 0.162 g/cc. The result cited in the table indicated good flow as it 
varied from 20 to 30. In addition to that, carr’s index was found to 
vary from 11.84 to 31.41, which indicated good compressibility. 
Physical characterization of carvedilol phosphate tablets with 
floating polymers 
Physical characterization of carvedilol phosphate tablets formulated 
with floating polymers was evaluated and displayed in table 4. The 
hardness of tables ranged from 3.8 kg/cm2 to 4.3 kg/cm2. During the 
study, it observed that a formulation having HPMC grades of low 
viscosity has a low swelling index as compared to higher viscosity 
grades of HPMC. As per US pharmacopoeia, the maximum 
percentage friability should not exceed 1%. The prepared tablets lie 
within the acceptable and passed the friability test ranged from 0.33 
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to 0.44. All the tablets have shown excellent uniform thickness and 
no such variation was found. All the tablets have shown acceptable 
tablet densities between 0.968 to 0.996 g/cc, which were less than 
that of gastric fluid (1.004 g/cc), resulting in all of them to float. 
Drug content study of prepared batches at various concentrations 
with the drug has shown majorly drug content in between 90-94%. 
 
Table 3: Evaluation of pre-compression parameters 
Batch 
code 




Tapped density(g/cc) (X±SD) Hausner’s ratio Compressibility index 
(Carr’s index) 
f1 20.34±0.04 0.114±0.03 0.134±0.04 1.17 14.92 
f2 21.32±0.12 0.106±0.02 0.122±0.03 1.15 13.11 
f3 20.42±0.08 0.105±0.03 0.127±0.01 1.21 17.32 
f4 20.52±0.6 0.129±0.02 0.148±0.03 1.14 12.83 
f5 20.47±0.22 0.122±0.03 0.154±0.02 1.26 20.78 
f6 24.28±0.34 0.135±0.02 0.162±0.01 1.2 16.66 
f7 23.56±0.4 0.134±0.01 0.152±0.03 1.13 11.84 
f8 25.28±0.26 0.107±0.02 0.156±0.02 1.45 31.41 
f9 29.88±0.24 0.129±0.03 0.152±0.02 1.17 15.13 
Data are represented as mean(X)±standard deviation (SD), n=3 
 
Evaluation of in vitro buoyancy and total floating time  
Lag time and total floating time were performed visually. The 
evaluation of prepared floating tablet batches have shown that 
batches f1, f2, f4, f5, f7, f8, were having a lag time between 36-80 s 
and total floating time between 14-23 h and batches f3, f6, f9 were 
having lag time between 112-155 seconds and total floating time 
between 21-27 h. This study suggested that as the quantity of HPMC 
increased in the formulation, lag time and total floating time of tablet 
increased. The f9 batch was selected in order to produce tables with 
good gel strength, entrapping carbon dioxide gas, imparting stability 
and persistent buoyancy up to 27 h. 
  
































f1 346±0.2 3.9±1.01 0.34±0.02 3.46±0.6 0.974 8.26 36±6 16±3 90±1.24 
f2 351±0.5 3.8±1.04 0.33±0.03 3.3±0.8 0.982 26.33 40±8 18±1.6 91±2.46 
f3 348±0.5 3.9±1.05 0.33±0.05 3.5±0.9 0.996 45.5 125±6 23±2.4 92±1.48 
f4 344±0.5 4.3±1.02 0.44±0.11 3.48±0.5 0.968 8.6 80±4 14±2.6 90±1.54 
f5 348±0.2 3.9±0.8 0.42±0.2 3.57±0.7 0.976 18.36 65±7 16±1.8 91±1.65 
f6 348±0.6 4.2±0.9 0.37±0.12 3.6±0.5 0.985 26.2 155±4 21±0.6 92±1.74 
f7 352±0.4 4.1±1.17 0.43±0.16 3.42±0.8 0.979 8.60 52±6 23±0.8 92±1.82 
f8 351±0.6 4.1±1.25 0.42±0.08 3.7±0.4 0.986 18.36 56±9 22±0.9 93±1.42 
f9 349±0.4 3.8±1.1 0.35±0.1 3.8±0.8 0.989 26.2 112±8 27±1.4 94±1.84 
Data are represented as mean(X)±standard deviation (SD), n=3 
 
Dissolution studies of carvedilol phosphate tablets with floating 
polymers 
The formulated batches f1 to f9 were subjected to drug release 
studies in dissolution media of 0.1N HCl. The formulation f1-f3 those 
containing drug and HPMC K4, the maximum amount of the drug 
was released in f2 of 91.3% in 8h. Among the f4-f6 containing K100, 
the maximum amount of the drug was released in f4 of 90.5% in 6h. 
Similarly in f7–f9, containing K15, the maximum amount of the drug 
was released in f9 of 95.3% in 16 h as displayed in table 5. From 
these studies, based on drug release profile and duration of release, 
batch f9 was selected as the best batch. 
 
Table 5: % Release of drug formulated with floating polymers 
Dissolution 
medium 
Time (h) f1 f2 f3 f4 f5 f6 f7 f8 f9 
  HPMC K4  HPMC K100  HPMC K15 
0.1N HCL  1 26.1 28.2 29.5 15.2 17.1 18.2 16.6 5.6 3.6 
 2 38.2 35.5 36.5 26.6 28.2 29.1 22.5 12.6 9.8 
 3 49.1 48.1 47.2 40.5 65.5 68.2 33.5 18.5 15.3 
 4 69.3 69.3 66.2 65.5 72.5 78.3 46.6 28.5 21.2 
 5 77.2 75.5 77.3 79.5 83.2 84.1 56.2 36.5 29.8 
 6 80.2 81.1 88.2 90.5 90.2 90.1 65.3 42.5 37.2 
 7 91.2 86.2 89.2 -- -- -- 75.5 50.5 43.1 
 8 -- 91.3 91.1 -- -- -- 82.5 60.2 54.2 
10 -- -- -- -- -- -- 90.5 75.2 68.3 
12 -- -- -- -- -- -- -- 85.2 78.6 
14 -- -- -- -- -- -- -- 92.5 89.6 
16 -- -- -- -- -- -- -- -- 95.3 
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The physical characterization of carvedilol phosphate tablets 
formulated with super disintegrants 
Physical characterization of carvedilol phosphate tablets formulated 
with super disintegrating polymers was evaluated and displayed in 
table 6. The hardness of tables ranged from 3.1 kg/cm2 to 3.3 kg/cm2
 
. 
The disintegration times for prepared batches have shown 36 to 87 
seconds. During the study, it observed that a formulation having 
increased super disintegrates concentration has less disintegration 
time. All the prepared tablets lie within the acceptable and passed the 
friability test ranged from 0.42 to 0.77. Drug content study of prepared 
batches at various concentrations with the drug has shown majorly 
drug content in between 95-98%. The sf9 batch was selected in order 
to produce a tablet with faster disintegrating within 36 s. 
Table 6: Post compression studies of carvedilol phosphate tablets formulated with crospovidone (sf1-sf3), CCS (sf4-sf6) and SSG (sf7-sf9) 








Drug content (%) 
(X±SD) 
sf1 100±0.79 3.1±0.2 0.56±0.12 87±3 95±1.82 
sf2 108±0.98 3.2±0.2 0.43±0.3 68±5 96±1.44 
sf3 107±0.69 3.1±0.2 0.43±0.02 44±12 95±1.47 
sf4 101±0.67 3.3±0.2 0.54±0.01 63±9 95±1.64 
sf5 105±0.21 3.2±0.2 0.42±0.21 55±8 96±1.32 
sf6 96±0.1 3.1±0.2 0.77±0.12 43±7 98±1.24 
sf7 101±0.67 3.2±0.2 0.53±0.14 54±15 95±1.28 
sf8 104±0.21 3.2±0.2 0.62±0.22 48±8 96±1.46 
sf9 99±0.1 3.1±0.2 0.65±0.16 36±4 98±1.78 
Data are represented as mean±standard deviation (SD), n=3 
 
The dissolution studies of tablets formulated with super 
disintegrants 
The formulated batches sf1 to sf9 were subjected to drug release 
studies in dissolution media of 0.1N HCL. The formulation sf1-sf3 
those containing drug and crospovidone, the maximum amount of 
the drug was released in sf3 to 92.2% in 20 min. Among the sf4-sf6 
containing CCS, the maximum amount of the drug was released in 
sf4 of 92.4% in 20 min. Similarly in sf7-sf9 containing SSG the 
maximum amount of the drug was released in sf9 of 97.2% in 15 min 
as displayed in table 7. From these studies based on drug release 
and time to disintegrate, batch sf9 was selected as the best batch. 
 
Table 7: % drug release of tablets with different concentrations of super disintegrants 
Dissolution medium Time 
(Min) 
sf1 sf2 sf3 sf4 sf5 sf6 sf7 sf8 sf9 
Crospovidone CCS SSG 
0.1N HCL 5 18.2 19.2 20.52 19.8 20.1 22.1 23.1 25.2 30.5 
10 48.3 48.1 68.2 66.5 65.2 68.2 59.2 64.5 67.34 
15 76.1 68.3 82.1 83.1 82.2 82.1 90.2 95.5 97.2 
20 85.5 87.1 92.3 92.4 92.1 92.2 -- -- -- 
25 90.2 90.2 -- -- -- -- -- -- -- 
 
Drug release study of compression coating floating tablet in 
dissolution apparatus 
For confirmation and optimization of compression coating floating 
tablet, the individual batches f1-f9 for controlled release formulation 
as core tablet and powder blend as per sf1 to sf9 for immediate 
release were formulated as F1 to F9 and evaluated for release of 
carvedilol phosphate in a dissolution medium of 0.1N HCl. 
Immediate release profile was studied at 5, 10, 15, 20, 25 min 
respectively and cumulatively calculated for controlled release 
profile in 1 h to 16 h. From the above studies, it was concluded that 
the release rate of F9 has shown a steady immediate release within 
15 min similar to that of an individual batch of sf9 and the 
concentration became more flatter with a continuous release for 16h 
similar to that of an individual batch of f9. The graphical release 
pattern is displayed in fig. 1. 
 
 
Fig. 1: In vitro dissolution study of all formulations (F1-F9), (Data are represented as mean±SD, n=3) 
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Drug release study of reproduced batches of the best batch 
Further to confirm the release pattern and to observe the 
reproducibility of the best batch again five trial batches of F9 were 
compressed (T1 to T5) and their release profile was studied. The 
average release of these five batches and their standard deviations 
was plotted in fig. 2. From the above studies, it was concluded that 
the release rate was maintaining immediate release as well as a 
controlled release for continuously up to 16 h, which were 
reproducible and predictable in nature. 
  
 
Fig. 2: Average cumulative % drug release of compression coating floating tablets (T1–T5) with error bars, n=5 
 
Drug-excipients interaction studies  
Drug-excipients interaction studies were performed using FTIR 
spectrophotometer. The FTIR spectra for the formulation and pure 
drug are shown in fig. 3-5.  
Characteristics peaks obtained for the pure drug correlated well 
with that of the formulation peaks. These indicated that the drug 
was compatible with the formulation components and there 




Fig. 3: IR Spectrum for carvedilol phosphate 
 
 
Fig. 4: IR Spectrum for carvedilol phosphate with HPMC K15 optimized formula 
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Fig. 5: IR Spectrum for carvedilol phosphate with SSG optimized formula 
 
Table 8: Accelerated stability studies report of compression coating floating tablet 
Period  Dissolution (%) Assay (%) Appearance 
1st h 2nd h 12th h 16th h 
Initial (0 mo) 50.4±1.2 53.5±2.3 87.9±2.6 96.4±1.7 96.2±3.2 Off white 
Intermediate (3 mo) 50.8±1.8 52.4±3.1 84.6±1.7 94.5±1.4 95.3±2.3 Off white 
Final (6 mo) 51.3±1.4 54.1±3.2 87.7±1.5 95.6±2.1 95.4±2.4 Off white 
Data are represented as mean±SD, n=3 
 
Accelerated stability study of best batch 
The accelerated stability study report revealed that the formulation 
has not undergone any physical or chemical degradation during the 
period. There was no significance change in the in vitro
Pharmacokinetic report  
 drug release 
and drug assay as shown in table 8. 
The kinetic summary from fig. 6 to fig. 9 revealed that carvedilol 
phosphate extended-release tablets followed zero-order kinetics as 
the regression coefficients approached unity, indicating that the 
drug release was independent of drug concentration.  
The Higuchi plots also has shown good linearity, indicating that the 
drug release was proportional to the square root of time and the 
drug was released at a slower rate. 
 
 
Fig. 6: Zero order drug release of carvedilol phosphate in f9 
 
Fig. 7: First order drug release of carvedilol phosphate in f9 
 
 
Fig. 8: Higuchi graph of drug release of carvedilol phosphate in f9
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Fig. 9: Peppas graph of drug release of carvedilol phosphate in f9 
 
CONCLUSION 
During this study, both immediate release and controlled release 
tablets of carvedilol phosphate were formulated by designing 
compression coating floating drug delivery system. Among 
formulated batches based on performance with respected to 
buoyancy, log time, release pattern F9 was selected as a best 
formula. For the better onset of action, immediate release coat has 
provided dissolution within 15 min and the controlled release 
floating core tablet has shown a buoyancy time of 36s with total 
floating time for 16h. The newly developed tablets also have shown 
both pre-compression and post-compression characters within 
expectable limits. There were no formulation problems associated 
with the optimized batch of carvedilol phosphate compression 
coating floating tablets. The tablets also passed the short-term 
accelerated stability studies, indicating that the physical and 
chemical stability of the product. The compression coating floating 
tablet was the best dosage form for the treatment of hypertension 
because it was reported the constant drug action which was needed 
the entire day and it would improve maximum therapeutic efficacy 
with patient compliance.  
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